801. Deputy Sorca Clarke asked the Minister for Health if a person with a diagnosed psychiatric disorder can make an advanced directive or decision to the right to taper their medication; if so, the process to do so; and if she will make a statement on the matter. [65150/25]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
838. Deputy John Connolly asked the Minister for Health for an update on the consideration within her Department towards the inclusion of caplacizumab on the drug reimbursement scheme; and if she will make a statement on the matter. [65371/25]
839. Deputy John Connolly asked the Minister for Health for an update on the consideration within her Department towards the inclusion of selpercatinib (also pralsetinib) on the drug reimbursement scheme; and if she will make a statement on the matter. [65372/25]
843. Deputy Pádraig O'Sullivan asked the Minister for Health if she has reviewed the joint statement from groups regarding changing the reimbursement arrangements for high-protein oral nutritional supplements (ONS) (details supplied); if she is aware that the expert view has warned that such changes would undermine evidence-based nutrition support for vulnerable patients; if high-protein ONS will remain available to …
844. Deputy Cian O'Callaghan asked the Minister for Health her Department’s plan to deregulate the use of a medication (details supplied) in an effort to help reduce drug deaths; and if she will make a statement on the matter. [65431/25]
879. Deputy Aengus Ó Snodaigh asked the Minister for Health if blister-packing of medications by pharmacists will be charged for in the near future (details supplied); and if she will make a statement on the matter. [65697/25]
905. Deputy Emer Currie asked the Minister for Health if the free pharmacist blister packing service will be available in January 2026; and if she will make a statement on the matter. [65900/25]
906. Deputy Michael Fitzmaurice asked the Minister for Health further to Parliamentary Question No. 1825 of 4 November 2025, if she will insure that the most vulnerable and disadvantaged people that are incapable of safely and effectively managing their medication regimen, will not be impacted by the ceasing of free dispensing of prescription medication in blister packs in January 2026 (details supplied); and if she …
907. Deputy Michael Fitzmaurice asked the Minister for Health if there is an established set of criteria put in place to assist pharmacies when assessing eligibility to receive free dispensing of prescription medication in blister packs; and if she will make a statement on the matter. [65925/25]
931. Deputy Barry Heneghan asked the Minister for Health the reasons for the introduction of a charge for blister packaging by pharmacists from January 2026; if she acknowledges that many of the people who rely on this service live with serious medical conditions and have very limited income; and if she will make a statement on the matter. [66130/25]
932. Deputy Barry Heneghan asked the Minister for Health if she will consider introducing financial supports or exemptions for patients who rely on blister packaging because of complex medical conditions, cognitive difficulties or disability, given that any additional charge would disproportionately impact those on low incomes; and if she will make a statement on the matter. [66131/25]
933. Deputy Barry Heneghan asked the Minister for Health if she will engage with the pharmacy sector to ensure that any changes to blister packaging provision do not reduce medication safety for vulnerable patients who depend on organised dosing systems; and if she will make a statement on the matter. [66132/25]
934. Deputy Barry Heneghan asked the Minister for Health if her Department carried out any assessment of the financial or clinical impact of introducing a blister pack charge, particularly for older people and people with disabilities; and if she will make a statement on the matter. [66133/25]
85. Deputy Martin Daly asked the Minister for Health the reason the osteoporosis drug Prolia, denosumab, is not routinely available free of charge to men with confirmed debilitating osteoporosis in Ireland in the same manner as it is available to women in equivalent clinical circumstances; and the steps her Department is taking to ensure equitable access for male patients in the Roscommon–Galway constituency who coul…
93. Deputy Mairéad Farrell asked the Minister for Health if the decision not to reimburse for belimumab will be reviewed; and if she will make a statement on the matter. [64337/25]
115. Deputy Aindrias Moynihan asked the Minister for Health the up-to-date position on the MCAP review; the way in which and when the membership was constituted; the frequency with which they have met; and when they are due to report; and if she will make a statement on the matter. [64361/25]
118. Deputy Seán Crowe asked the Minister for Health for an update on the approval status of the drug givinostat; if officials from her Department have been in contact with their counterparts in the North of Ireland to examine the possibility of children with Duchenne muscular dystrophy accessing treatment in the North as an interim measure; if not, to outline the barriers to them doing so; and if she will make a sta…
203. Deputy Pádraig O'Sullivan asked the Minister for Health the progress made by her Department regarding the Programme for Government commitment to explore early access schemes for medicines; and if she will make a statement on the matter. [63426/25]
651. Deputy Barry Heneghan asked the Minister for Health if she will examine the current regulatory status of naloxone and consider allowing approved formulations to be made available over-the-counter in order to improve timely access to this emergency medication, in line with international practice; and if she will make a statement on the matter. [64949/25]
652. Deputy Barry Heneghan asked the Minister for Health the current supply pathways through which community and voluntary organisations can access and distribute naloxone; if consideration is being given to expanding these pathways to reduce delays; and if she will make a statement on the matter. [64953/25]
665. Deputy Cormac Devlin asked the Minister for Health to report on the engagement to date between her Department, the HSE and the manufacturer of the Omnipod 5 tubeless hybrid closed-loop insulin delivery system regarding its introduction to the Irish market; if a pricing and reimbursement application has been submitted under the Health (Pricing and Supply of Medical Goods) Act 2013; and if she will make a statemen…
666. Deputy Cormac Devlin asked the Minister for Health if the HSE, NCPE or her Department have undertaken, or plan to undertake, a clinical and cost-effectiveness assessment of the Omnipod 5 tubeless hybrid closed-loop insulin pump system, having regard to its availability and funded use in the UK and other EU member states; if so, to outline the status and expected timelines for a decision; and if she will make a s…
667. Deputy Cormac Devlin asked the Minister for Health her views on the potential role of the Omnipod 5 tubeless hybrid closed-loop insulin system in expanding patient choice for people with type 1 diabetes, including children, people with disabilities, needle or tube aversion, and those with high treatment burden; if she will request the HSE to examine its potential use within the national diabetes technology pathw…
1124. Deputy David Cullinane asked the Minister for Health when a medical product (details supplied) will be available for reimbursement; and if she will make a statement on the matter. [63710/25]
442. Deputy Pádraig Rice asked the Minister for Health further to Parliamentary Question No. 609 of 23 September 2025, to clarify if a group were excluded from the costing for the free hormone replacement therapy (HRT) scheme; if so, to outline how, given the details of an internal communication in relation to the basis for the costing (details supplied); and if she will make a statement on the matter. [62378/25]